From investor presentation March 2015 for capital raising.
Use of funds > These funds are budgeted to last until the end of Q3 2015 which will be following the expected release of pivotal clinical data relating to the INV103 (ala-Cpn10) and INV102 (nadolol) programs (anticipated within 3-4 months). It is expected that positive clinical data from one or both of these trials will position the company to negotiate a strategic investment in the company by a recognised biotech fund or provide a platform for a trade sale of the company or its assets.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.6¢ |
Change
-0.001(1.03%) |
Mkt cap ! $8.199M | |||
| Open | High | Low | Value | Volume |
| 9.7¢ | 9.9¢ | 9.5¢ | $8.335K | 86.22K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20643 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 256280 | 4 |
View Market Depth
| Last trade - 14.40pm 28/07/2025 (20 minute delay) ? |
| IVX (ASX) Chart |